本研究主要探討重組人類γ干擾素於大腸桿菌與植物細胞內的生合成狀況，以及生產高應用性與高附加價值的γ干擾素單株與多株抗體。在大腸桿菌的實驗中，我們採用四種不同的重組γ干擾素表現質體來測試細胞內重組γ干擾素表現的情形，結果顯示利用pET28a質體建構的表現質體具備最高的重組γ干擾素生合成能力，且利用BL21(DE3) 菌株做為寄主時，30至300 μM的IPTG濃度能使細胞內的重組γ干擾素表現量達到最高，此時每公升菌液可表現出約200 mg的重組γ干擾素，佔大腸桿菌細胞內總蛋白質的46.5%，若利用固相金屬親和性層析法進行純化，則純化後可得到純度約95%重組γ干擾素，回收率約為48.4%。若利用低溫誘導或復性策略來取得水溶性重組γ干擾素，則發現水溶性重組γ干擾素會在緩衝液中迅速變性沉澱，雖然甘油與精胺酸（arginine-HCl）等添加劑能夠延緩水溶性重組γ干擾素的沉澱，但實驗顯示該水溶性重組γ干擾素仍沒有顯著的抗病毒活性。植物細胞的部份則採用水稻及蕃茄原生質體來進行重組γ干擾素生合成的初步探討，在挑選出具備最高活性的玉米ZmUbq-1啟動子後，建構出以ZmUbq-1啟動子調控表現的基因表現卡匣供轉形實驗使用，而暫時性表現實驗的結果顯示基因轉錄作用雖正常進行，但重組γ干擾素無法於水稻原生質體中有效生合成與累積。而在γ干擾素單株抗體生產部份，本實驗利用細菌生合成之重組γ干擾素生產出九株適用於ELISA實驗的單株抗體，而其中三個單株抗體更可兼用於免疫染色實驗（Western blot），且抗體效價很好，在0.25 μg/ml的抗體濃度下，即可清楚辨識到0.3至1 ng以下的γ干擾素。在多株抗體的生產部分，則收集到總體積超過200 ml的多株抗體血清，實驗結果顯示多株抗體血清的效價亦相當高且具有一致性，即使將血清稀釋三十萬倍後，仍可明顯辨識到5 ng以下的γ干擾素。

The present studies describe our attempts to express the recombinant human interferon-gamma (rh-IFNγ) and to generate antibodies directed to rh-IFNγ. In the experiments to express rh-IFNγ in E. coli, we have scrutinized four different expression vectors and found that pET28a was most suitable for rh-IFNγ expression in E. coli strain BL21(DE3). By adding inducer IPTG to final concentration of 30~300 μM, the rh-IFNγ was expressed in E. coli at a high level of near 200 mg/L, which accounted for 46.5% of total proteins in the cell. By adsorption to and elution from an immobilized nickel column, the collected rh-IFNγ was near 95% pure and the recovery yield was about 48.4%. To prepare soluble rh-IFNγ for antiviral assay, the recombinant protein was expressed at 16°C and either glycerol or arginine was included as protein stabilizer. Nevertheless, no significant antiviral effect has been demonstrated to the rh-IFNγ thus far. In the experiments to express rh-IFNγ in plant cells, we have constructed and tested a number of gene expression cassettes. The results of transient expression assays revealed that maize ZmUbq-1 promoter and CaMV 35S promoter had the highest activity to drive gene expression in rice and tomato protoplasts, respectively. However, rice protoplasts transformed with IFNγ gene driven by ZmUbq-1 promoter were found to accumulate no detectable amount of rh-IFNγ protein. In the experiments to generate monoclonal antibodies directed to rh-IFNγ, a total of 9 cell lines were successfully screened. Among them, six lines are effective for ELISA, while the other three lines worked well for both ELISA and immunoblot assay. In addition, we have also collected more than 200 ml high-titer rabbit anti-sera against rh-IFNγ, which could detect 5 ng antigen in an immunoblot assay even being diluted by 300000-fold.

1. Akbar SM, Inaba K, Onji M. (1996) Upregulation of MHC class II antigen on dendritic cells from hepatitis B virus transgenic mice by interferon-gamma: abrogation of immune response defect to a T-cell-dependent antigen. Immunology. 87: 519-527.
2. Arora D, Khanna N. (1996) Method for increasing the yield of properly folded recombinant human gamma interferon from inclusion bodies. J Biotechnol. 52: 127-133.
3. Baneyx F, Mujacic M. (2004) Recombinant protein folding and misfolding in Escherichia coli. Nat Biotechnol. 22: 1399-1408.
4. Battraw MJ, Hall TC. (1990) Histochemical analysis of CaMV 35S promoter- beta-glucuronidase gene expression in transgenic rice plants. Plant Mol Biol. 15: 527-538.
5. Bitter GA, Egan KM. (1988) Expression of interferon-gamma from hybrid yeast GPD promoters containing upstream regulatory sequences from the GAL1-GAL10 intergenic region. Gene. 69: 193-207.
6. Blum H, Beier H, Gross HJ. (1987) Improved silver staining of plant proteins, RNA and DNA in polyacrylamide gels. Electrophoresis 8: 93-99.
7. Bradford MM. (1976) A rapid and sensitive method for the quantitation of microgram quantities og protein utilizing the principle of protein-dye binding. Anal Biochem. 72: 248-254.
8. Bunn PA Jr, Norris DA. (1990) The therapeutic role of interferons and monoclonal antibodies in cutaneous T-cell lymphomas. J Invest Dermatol. 95: 209S-212S.
9. Carrio MM, Villaverde A. (2002) Construction and deconstruction of bacterial inclusion bodies. J Biotechnol. 96: 13-12.
10. Chang TT, Stevens SR. (2002) Atopic dermatitis: the role of recombinant interferon-gamma therapy. Am J Clin Dermatol. 3:175-183.
11. Chen TL, Lin YL, Lee YL, Yang NS, Chan MT. (2004) Expression of bioactive human interferon-gamma in transgenic rice cell suspension cultures. Transgenic Res. 13: 499-510.
12. Christensen AH, Quail PH. (1996) Ubiquitin promoter-based vectors for high-level expression of selectable and/or screenable marker genes in monocotyledonous plants. Transgenic Res. 5: 213-218.
13. Clark ED. (2001) Protein refolding for industrial processes. Curr Opin Biotechnol. 12: 202-207.
14. Crawfoerd JH, McIntosh. (1925) Cited in: Sollman, a manual of pharmacology and its applications to therapeutics and toxicology. English edition, 1957. Saunders company, Philadelphia and London. p. 1051.
15. De Cosa B, Moar W, Lee SB, Miller M, Daniell H. (2001) Overexpression of the Bt cry2Aa2 operon in chloroplasts leads to formation of insecticidal crystals. Nat Biotechnol. 19: 71-74.
16. Derynck R, Singh A, Goeddel DV. (1983) Expression of the human interferon-gamma cDNA in yeast. Nucleic Acids Res. 11: 1819-1837.
17. Ebisu S, Takagi H, Kadowaki K, Yamagata H, Udaka S. (1996) The efficient production of human epidermal growth factor by Bacillus brevis. Ann N Y Acad Sci., 782: 115-122.
18. Fischer R, Emans N. (2000) Molecular farming of pharmaceutical proteins. Transgenic Res. 9: 279-299
19. Ganes CS, Lengyel P. (1992) The interferon system. A bird’s eye new of its biochemistry. J Biol Chem. 267: 5017-5020.
20. Gao YG, Guan YX, Yao SJ, Cho MG. (2003) On-column refolding of recombinant human interferon-gamma with an immobilized chaperone fragment. Biotechnol Prog. 19: 915-920.
21. Geng X, Bai Q, Zhang Y, Li X, Wu D. (2004) Refolding and purification of interferon-gamma in industry by hydrophobic interaction chromatography. J Biotechnol. 113: 137-49.
22. Giddings G, Allison G, Brooks D, Carter A. (2000) Transgenic plants as factories for biopharmaceuticals. Nat Biotechnol. 18: 1151-1155.
23. Goeddel DV, Heyneker HL, Hozumi T, Arentzen R, Itakura K, Yansura DG, Ross MJ, Miozzari G, Crea R, Seeburg PH. (1979) Direct expression in Escherichia coli of a DNA sequence coding for human growth hormone. Nature. 281: 544-548.
24. Goeddel DV, Kleid DG, Bolivar F, Heyneker HL, Yansura DG, Crea R, Hirose T, Kraszewski A, Itakura K, Riggs AD. (1979) Expression in Escherichia coli of chemically synthesized genes for human insulin. Proc Natl Acad Sci. 76: 106-110.
25. Goff SA, Ricke D, Lan TH, Presting G, Wang R, Dunn M, Glazebrook J, Sessions A, Oeller P, Varma H, Hadley D, Hutchison D, Martin C, Katagiri F, Lange BM, Moughamer T, Xia Y, Budworth P, Zhong J, Miguel T, Paszkowski U, Zhang S, Colbert M, Sun WL, Chen L, Cooper B, Park S, Wood TC, Mao L, Quail P, Wing R, Dean R, Yu Y, Zharkikh A, Shen R, Sahasrabudhe S, Thomas A, Cannings R, Gutin A, Pruss D, Reid J, Tavtigian S, Mitchell J, Eldredge G, Scholl T, Miller RM, Bhatnagar S, Adey N, Rubano T, Tusneem N, Robinson R, Feldhaus J, Macalma T, Oliphant A, Briggs S. (2002) A draft sequence of the rice genome (Oryza sativa L. ssp. japonica). Science. 296: 92-100.
26. Goldsby RA, Kindt TJ, Osborne BA, Kuby J. (1992) Immunology. 276-297.
27. Goldstein DA , Thomas JA. (2004) Biopharmaceuticals derived from genetically modified plants. QJM. 97: 705-716.
28. Gottlöber P, Steinert M, Bahren W, Weber L, Gerngross H, Peter RU. (1998) Interferon-gamma in 5 patients with cutaneous radiation syndrome after radiation therapy. Int J Radiat Oncol Biol Phys. 50:159-166.
29. Grassegger A, Höpfl R. (2004) Significance of the cytokine interferon gamma in clinical dermatology. Clin Exp Dermatol. 29:584-8.
30. Gray PW, Leung DW, Pennica D, Yelverton E, Najarian R, Simonsen CC, Derynck R, Sherwood PJ, Wallace DM, Berger SL, Levinson AD, Goeddel DV. (1982) Expression of human immune interferon cDNA in E. coli and monkey cells. Nature. 295: 503-508.
31. Gray PW, Rinderknecht EH. (2002) Recombinant gamma interferons having enhanced stability and methods therefor. US patent #6497871.
32. Green J, Vain P, Fearnehough MT, Worland B, Snape JW, Atkinson HJ. (2002) Analysis of the expression patterns of the Arabidopsis thaliana tubulin-1 and Zea mays ubiquitin-1 promoters in rice plants in association with nematode infection. Physiol. Mol. Plant Pathol., 60: 197-205.
33. Gross G. (1997) Therapy of human paillomavirus infection and associated epithelial tumors. Intervirology. 40: 368-377.
34. Guttman C. (1997) Interferon-gamma may be next treatment option for Atopic Dermatitis. Dermatology Times. 18: 13.
35. Gutmann S, Zawatzky R, Muller M. (2005) Characterisation and quantification of equine interferon gamma. Vet Immunol Immunopathol. 104: 105-115.
36. Hellwig S, Drossard J, Twyman RM, Fischer R. (2004) Plant cell cultures for the production of recombinant proteins. Nat Biotechnol. 22: 1415-1422.
37. Hong CY, Cheng KJ, Tseng TH, Wang CS, Liu LF, Yu SM. (2004) Production of two highly active bacterial phytases with broad pH optima in germinated transgenic rice seeds. Transgenic Res., 13: 29-39.
38. Horn ME, Woodard SL, Howard JA. (2004) Plant molecular farming: systems and products. Plant Cell Rep. 22: 711-720.
39. ICGDCSG, the international chronic granulomatous disease cooperative study group. (1991) A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med. 324:509-516.
40. Isaacs A, Lindenmann J. (1957) Virus interference. I. The interferon. Proc R Soc Lond B Biol Sci. 147: 258-267.
41. Jacobsen JV, Gubler F, and Chandler PM. (1995) Plant Hormones: Physiology, Biochemistry, and Molecular Biology. 247-271.
42. Janeway CA, Travers P, Walport M, Capra JD. (1999) ImmunoBiology: The Immune System in Health and Disease. 4th edition. Elsevier Science Ltd/Garland Publishing. 288, 385-386, 397, 438.
43. Jang IC, Nahm BH, Kim JK. (1999) Subcellular targeting of green fluorescent protein to plastids in transgenic rice plants provides a high-level expression system. Mol Breed. 5: 453-461.
44. Jang IC, Choi WB, Lee KH, Song SI, Nahm BH, Kim JK. (2002) High-level and ubiquitous expression of the rice cytochrome c gene OsCc1 and its promoter activity in transgenic plants provides a useful promoter for transgenesis of monocots. Plant Physiol. 129: 1473-1481.
45. Jimenez SA, Freundlich B, Rosenbloom J. (1984) Selective inhibition of human diploid fibroblast collagen synthesis by interferons. J Clin Invest. 74:1112-1116.
46. Jin T, Guan YX, Yao SJ, Lin DQ, Cho MG. (2005) On-column refolding of recombinant human interferon-gamma inclusion bodies by expanded bed adsorption chromatography. Biotechnol Bioeng. [Epub ahead of print]
47. Kentaro S, Motonori K, Shinsuke F, Tadayuki I, Masahiro T. (2002) Biophysical effect of amino acids on the prevention of protein aggregation. J Biochem. 132: 591-595.
48. Key K. (1994) NIH reports on treatment of TB with IFN-gamma. AIDS Weekly: 19.
49. Key LL Jr, Rodriguiz RM, Willi SM, Wright NM, Hatcher HC, Eyre DR, Cure JK, Griffin PP, Ries WL. (1995) Long-term treatment of osteopetrosis with recombinant human interferon gamma. N Engl J Med. 332: 1594-1599.
50. Kedzierska K, Azzam R, Ellery P, Mak J, Jaworowski A, Crowe SM. (2003) Defective phagocytosis by human monocyte/macrophages following HIV-1 infection: underlying mechanisms and modulation by adjunctive cytokine therapy. J Clin Virol. 26:247-63.
51. Kendrick BS, Carpenter JF, Cleland JL, Randolph TW. (1998) A transient expansion of the native state precedes aggregation of recombinant human interferon-gamma. Proc Natl Acad Sci U S A. 95: 14142-14146.
52. Khalilzadeh R, Shojaosadati SA, Maghsoudi N, Mohammadian-Mosaabadi J, Mohammadi MR, Bahrami A, Maleksabet N, Nassiri-Khalilli MA, Ebrahimi M, Naderimanesh H. (2004) Process development for production of recombinant human interferon-gamma expressed in Escherichia coli. J Ind Microbiol Biotechnol. 31: 63-69.
53. Koprowski H, Yusibov V. (2001) The green revolution: plants as heterologous expression vectors. Vaccine. 19: 2735-2741.
54. Kung HF, Sugino H, Honda S. (1994) Immune Interferon. US patent #5278286.
55. Kyozuka J, McElroy D, Hayakawa T, Xie Y, Wu R, Shimamoto K. (1993) Light-regulated and cell-specific expression of tomato rbcS-gusA and rice rbcS-gusA fusion genes in transgenic rice. Plant Physiol. 102: 991-1000.
56. Leelavathi S, Reddy VS. (2003) Chloroplast expression of His-tagged GUS-fusions: A general strategy to overproduce and purify foreign proteins using transplastomic plants as bioreactors. Molecular breeding. 11: 49-58.
57. Lowey OH, Rosebrough NJ, Farr AL, Randall RJ. (1951) Protein measurement with the Folin phenol reagent. J Biol Chem. 193: 265-275.
58. Ma JK, Barros E, Bock R, Christou P, Dale PJ, Dix PJ, Fischer R, Irwin J, Mahoney R, Pezzotti M, Schillberg S, Sparrow P, Stoger E, Twyman RM; European Union Framework 6 Pharma-Planta Consortium. (2005) Molecular farming for new drugs and vaccines. Current perspectives on the production of pharmaceuticals in transgenic plants. EMBO Rep. 6: 593-599.
59. Ma JK, Drake PM, Christou P. (2003) The production of recombinant pharmaceutical proteins in plants. Nat Rev Genet. 4: 794-805.
60. Ma JK, Hiatt A, Hein M, Vine ND, Wang F, Stabila P, van Dolleweerd C, Mostov K, Lehner T. (1995) Generation and assembly of secretory antibodies in plants. Science. 268: 716-719.
61. Mahrle G, Schulze H-J. (1990) Recombinant interferon in dermatology. J Invest Dermatol. 95: 132-137.
62. Marble M. (1996) Malaria vaccines. Malaria Weekly: 8.
63. Markwell MA, Haas SM, Bieber LL, Tolbert NE. (1978) A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples. Anal Biochem. 87: 206-210.
64. Mason HS, Lam DMK, Arntzen CJ (1992) Expression of hepatitis B surface antigen in transgenic plants. Proc. Natl. Acad. Sci. 89: 11745-11749.
65. McElroy D, Zhang W, Cao J, Wu R. (1990) Isolation of an efficient actin promoter for use in rice transformation. Plant Cell. 2: 163-171.
66. Nagabhushan TL, Trotta PP, Le HV, Kosecki RA. (1985) Process for the purification of gamma interferon. US patent #4751078.
67. Negrutiu I, Gharti-Chhetri G. (1991) A laboratory guide for cellular and molecular plant biology. 162-164.
68. Newport MJ, Huxley CM, Huston S, Hawrylowicz C, Oostra B, Williamson R, Levin M. (1996) A mutation in the IFN-g receptor gene and suscepibility to mycobacterial infection. N Engl J Med. 335(26): 1941-1948.
69. O’Dell J, Guhrs KH, Grosse F, Conrad U. (2001) Production of spider silk proteins in tobacco and potato. Nature Boiotechnol. 19: 573-577.
70. Pechenov SE, Tikhonov RV, Shingarova LN, Korobko VG, Yakimov SA, Klyushnichenko VE, Babajantz AA, Beliaev DL, Kuznetzov VP, Shvetz VI, Wulfson AN. (2002) Methods for preparation of recombinant cytokine proteins V. mutant analogues of human interferon-gamma with higher stability and activity. Protein Expr Purif. 24: 173-180.
71. Pittet B, Rubbia-Brandt L, Desmouliere A, Sappino AP, Roggero P, Guerret S, Grimaud JA, Lacher R, Montandon D, Gabbiani G. (1994) Effect of gamma-interferon on the clinical and biologic evolution of hypertrophic scars and Dupuytren's disease: an open pilot study. Plast Reconstr Surg. 93:1224-1235.
72. Sheen J. (2001) Signal transduction in maize and arabidopsis mesophyll protoplasts. Plant Physiol. 127:1466-1475.
73. Shin YJ, Hong SY, Kwon TH, Jang YS, Yang MS. (2003) High level of expression of recombinant human granulocyte-macrophage colony stimulating factor in transgenic rice cell suspension culture. Biotechnol Bioeng., 82: 778-783.
74. Slodowski O, Bohm J, Schone B, Otto B. (1991) Carboxyterminal truncated rhuIFN-gamma with a substitution of Gln 133 or Ser 132 to leucine leads to higher biological activity than in the wild type. Eur J Biochem. 202: 1122-1140.
75. Stevens RC. (2000) Design of high-throughput methods of protein production for structural biology. Structure. 8: R177-185.
76. Terashima M, Murai Y, Kawamura M, Nakanishi S, Stoltz T, Chen L, Drohan W, Rodriguez RL, Katoh S. (1999) Production of functional human alpha 1-antitrypsin by plant cell culture. Appl Microbiol Biotechnol., 52: 516-523.
77. Tereda R, Shimamoto K. (1990) Expression of CaMV 35S-GUS gene in transgenic rice plants. Mol Gen Genet. 220: 389-392.
78. Vassileva-Atanassova A, Mironova R, Nacheva G, Ivanov I. (1999) N-terminal methionine in recombinant proteins expressed in two different Escherichia coli strains. J Biotechnol. 69: 63-67.
79. Vassileva-Atanassova A, Niwa T, Mironova R, Ivanov I. (2000) Mass-spectral analysis of human interferon-gamma and chloramphenicol acetyltransferase I produced in two Escherichia coli strains. J Biotechnol. 78: 61-67.
80. Ventura S, Villaverde A. (2006) Protein quality in bacterial inclusion bodies. Trends Biotechnol. 24: 179-185.
81. Vijay-Kumar S, Senadhi SE, Ealick SE, Nagabhushan TL, Trotta PP, Kosecki R, Reichert P, Bugg CE. (1987) Crystallization and preliminary X-ray investigation of a recombinant form of human gamma-interferon. J Biol Chem. 262: 4804-4805.
82. Wakimoto AJ, Tsunoda R, Okabe S, Yoshida Y, Aoyagi M, Hirakawa K, Hamada H. (1996) In vivo antitumor effect of cytotoxic T lymphocytes engineered to produce interferon-gamma by adenovirus-mediated genetic transduction. Biochem Biophys Res Commun. 218:164-170.
83. Weintraub JA, Hilton JF, White JM, Hoover CI, Wycoff KL, Yu L, Larrick JW, Featherstone JD. (2005) Clinical trial of a plant-derived antibody on recolonization of mutans streptococci. Caries Res. 39: 241-250.
84. Yashiro K, Lowenthal JW, O'Neil TE, Ebisu S, Takagi H, Moore RJ. (2001) High-level production of recombinant chicken interferon-gamma by Brevibacillus choshinensis. Protein Expr Purif. 23: 113-120.
85. Yu J, Hu S, Wang J, Wong GK, Li S, Liu B, Deng Y, Dai L, Zhou Y, Zhang X, Cao M, Liu J, Sun J, Tang J, Chen Y, Huang X, Lin W, Ye C, Tong W, Cong L, Geng J, Han Y, Li L, Li W, Hu G, Huang X, Li W, Li J, Liu Z, Li L, Liu J, Qi Q, Liu J, Li L, Li T, Wang X, Lu H, Wu T, Zhu M, Ni P, Han H, Dong W, Ren X, Feng X, Cui P, Li X, Wang H, Xu X, Zhai W, Xu Z, Zhang J, He S, Zhang J, Xu J, Zhang K, Zheng X, Dong J, Zeng W, Tao L, Ye J, Tan J, Ren X, Chen X, He J, Liu D, Tian W, Tian C, Xia H, Bao Q, Li G, Gao H, Cao T, Wang J, Zhao W, Li P, Chen W, Wang X, Zhang Y, Hu J, Wang J, Liu S, Yang J, Zhang G, Xiong Y, Li Z, Mao L, Zhou C, Zhu Z, Chen R, Hao B, Zheng W, Chen S, Guo W, Li G, Liu S, Tao M, Wang J, Zhu L, Yuan L, Yang H. (2002) A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science. 296: 79-92.
86. Yu SM, Kuo YH, Sheu G, Sheu YJ, Liu LF. (1991) Metabolic derepression of alpha-amylase gene expression in suspension cultured cells of rice. J. Biol. Chem., 266: 21131-21137.
87. Yu SM, Tzou WS, Lo WS, Kuo YH, Lee HT, Wu R. (1992) Regulation of alpha-amylase-encoding gene expression in germinating seeds and cultured cells of rice. Gene, 122: 247-253.
88. Zhang W, McElroy D, Wu R. (1991) Analysis of rice Act1 5' region activity in transgenic rice plants. Plant Cell. 3: 1155-1165.
89. Zhang Z, Tong KT, Belew M, Pettersson T, Janson JC. (1992) Production, purification and characterization of recombinant human interferon gamma. J Chromatogr. 604: 143-155.
90. Ziesche R, Hofbauer E, Wittmann K, Petkov V, Block LH. (1999) A preliminary study of long-term treatment with interferon gamma-1b and low-dose prednisolone in patients with idiopathic pulmonary fibrosis. N Engl J Med. 341: 1264-1269.
91. Zlateva T, Boteva R, Savato B, Tsanev R. (1999) Factors affecting the dissociation and aggregation of human interferon gamma. Int J Biol Macromol. 26: 357-362.